Clinical Trial

Skin Cancer Prevention

Study Description

Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial

A common long-term side effect of anti-rejection (immunosuppressant) medications is skin cancer. This pilot clinical trial evaluates the feasibility of conducting a larger pivotal trial to examine the efficacy and safety of nicotinamide for prevention of keratinocyte carcinoma in solid organ transplant recipients. This pilot trial will transition into the pivotal trial if all feasibility targets are met.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Nicotinamide

Oral nicotinamide (500 mg) twice daily for at least 52 weeks

Drug - Placebo oral capsule

Matching placebo taken twice daily for at least 52 weeks

Additional Information

Official Study Title

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: A Pilot, Placebo-controlled, Randomized Trial

Clinical Trial ID

NCT03769285

ParticipAid ID

bYEl0b